Interaction Checker
Potential Weak Interaction
Rilpivirine (RPV)
Dolutegravir/Lamivudine (DTG/3TC)
Quality of Evidence: Very Low
Summary:
Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with rilpivirine would be possible from a pharmacokinetic standpoint. Coadministration of rilpivirine (25 mg once daily) and dolutegravir (50 mg once daily) increased dolutegravir Cmax, AUC and Ctrough by 13%, 12% and 22%, respectively. Rilpivirine Cmax, AUC and Ctrough increased by 10%, 6% and 21%, respectively. No interaction is expected with lamivudine.
Description:
View all available interactions with Rilpivirine (RPV) by clicking here.
Copyright © 2025 The University of Liverpool. All rights reserved.